Showing 2791-2800 of 5621 results for "".
- Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with J&J’s Janssenhttps://modernod.com/news/morphic-therapeutic-enters-into-integrin-research-and-development-collaboration-with-jjs-janssen/2476272/Morphic Therapeutic announced that it has entered into a research and development collaboration with Johnson & Johnson’s subsidiary Janssen Biotech, to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies. Johnson &a
- Alcon Debuts iLux MGD Treatment System at SECOhttps://modernod.com/news/alcon-debuts-ilux-mgd-treatment-system-for-personalized-therapy-for-dry-eye-disease-at-seco/2476284/Alcon debuted the iLux MGD Treatment System at the SECO International 2019 annual meeting in New Orleans. The device, which received approval from the FDA in December 2017, helps eye care professionals provide comprehensive, in-office
- College of Optometrists in Vision Development & NORA Issue Joint Recommendation for Optometric Evaluation Following Brain Injuryhttps://modernod.com/news/college-of-optometrists-in-vision-development-nora-issue-joint-recommendation-for-optometric-evaluation-following-brain-injury/2476285/The College of Optometrists in Vision Development (COVD) and the Neuro Optometric Rehabilitation Association (NORA) issued a joint call-to-action to all healthcare professionals to consider the need for medical and/or functional optometric rehabilitation services for patients who have suffered a
- Ocugen Granted FDA Orphan Drug Designation for OCU400 Gene Therapy for Retinal Degenerative Diseasehttps://modernod.com/news/ocugen-granted-fda-orphan-drug-designation-for-ocu400-gene-therapy-for-retinal-degenerative-disease/2476293/Ocugen announced that the FDA granted orphan drug designation for its OCU400 gene therapy for the treatment of NR2E3 mutation-associated retinal degenerative disease. Inherited retinal diseases (IRDs) are caused by genetic mutations that are passed down within families and lead to visual i
- Zeiss Develops Multifunctional Smart Glasshttps://modernod.com/news/zeiss-develops-multifunctional-smart-glass/2476327/For the first time, a technology developed by Zeiss has made it possible to utilize transparent glass or plastic in a whole range of different ways, according to a company news release. The see-through surfaces with integrated, invisible microstructured optics permit a range of different applicat
- EyePoint Pharmaceuticals Announces US Commercial Launch of Yutiqhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-us-commercial-launch-of-yutiq/2476328/EyePoint Pharmaceuticals announced the US commercially launch of Yutiq, a 3-year micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. The company has also launched EyePoint Assist, a program to ensure access to Yutiq for eligible patients in
- Janssen Enters License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseaseshttps://modernod.com/news/janssen-enters-license-agreement-with-meiragtx-to-develop-gene-therapy-programs-for-inherited-retinal-diseases/2476340/The Janssen Pharmaceutical Companies of Johnson & Johnson announced a worldwide collaboration and license agreement with MeiraGTx Holdings, a clinical-stage gene therapy company, to develop, manufacture and commercialize its clinical stage inherited retinal disease portfolio, including leadin
- Aerie Pharmaceuticals Announces Acceptance of Its Investigational NDA for AR-1105 (Dexamethasone Intravitreal Implant)https://modernod.com/news/aerie-pharmaceuticals-announces-acceptance-of-its-investigational-nda-for-ar-1105-dexamethasone-intravitreal-implant/2476183/Aerie Pharmaceuticals announced that the FDA has reviewed the investigational new drug application (IND) for AR-1105 (dexamethasone intravitreal implant) and it is now in effect, allowing Aerie to initiate human studies in the treatment of macular edema due to retinal vein occlusion (RVO). The IN
- Ocular Therapeutix Submits Supplemental NDA for Dextenza for the Treatment of Postoperative Inflammationhttps://modernod.com/news/ocular-therapeutix-submits-supplemental-nda-for-dextenza-for-the-treatment-of-postoperative-inflammation/2476198/Ocular Therapeutix announced the submission of a supplemental new drug application (NDA) to the FDA for Dextenza (dexamethasone ophthalmic insert). The sNDA filing seeks to expand the current indication for Dextenza to include the treatment of ocular inflammation following ophthalmic surgery. The
- Global Demand for Refractive Surgery Growing After Economic Rebound in Major Marketshttps://modernod.com/news/global-demand-for-refractive-surgery-growing-after-economic-rebound-in-major-markets/2476207/Global demand for refractive surgery is expected to grow at a compound annual rate of 5.2 percent from 2018 to 2023, with annual surgical volume increasing from 4.3 million to 5.5 million procedures, according to the latest Market Scope estimates. Demand for refractive surgery has continued to gr